PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Lucia B. Jilaveanu, Fabio Parisi, Meaghan L. Barr, Christopher R. Zito, William Cruz‐Muñoz, Robert S. Kerbel, David L. Rimm, Marcus Bosenberg, Ruth Halaban, Yuval Kluger, Harriet M. KlugerClinical 2014 · DOI

Abstract

PLEKHA5 expression in melanoma tumors was associated with early development of brain metastases. Inhibition of PLEKHA5 might decrease passage across the BBB and decrease proliferation and survival of melanoma cells both in the brain and in extracerebral sites.
BibTeX
@inproceedings{jilaveanu2014plekha,
  author = {Lucia B. Jilaveanu and Fabio Parisi and Meaghan L. Barr and Christopher R. Zito and William Cruz‐Muñoz and Robert S. Kerbel and David L. Rimm and Marcus Bosenberg and Ruth Halaban and Yuval Kluger and Harriet M. Kluger},
  title = {{PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis}},
  booktitle = {Clinical},
  year = {2014},
  doi = {10.1158/1078-0432.ccr-14-0861},
}

Loading related content...

Figure